CellEmax

CellEmax is a future startup biotech from Sophia-Antipolis, spin-off of CNRS & INRIA, specialized in the fast identification of next-generation therapeutic targets for advanced Oncology. Our AI-powered discovery platform based on live-cell imaging identifies novel proteins to help re-sensitize cancer cells to the immune system applying our unique single-cell pharmacology approach. Discovering these targets will enable our industrial partners to design new targeted therapies but also rational cancer drug combination. Today, we are looking for our next collaborations and new talents to join the project.